Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.61 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.61 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.61 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7452595 | 0.91 | GPBAR1 (0.58) | PDE10AGPBAR1CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL10846145 | 0.87 | PDE10A (0.68) | PDE10AGPBAR1CYSLTR1CYSLTR2CYP1A2 | |
| SCHEMBL7457140 | 0.84 | PDE10A (0.60) | PDE10AGPBAR1CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL9719806 | 0.84 | PDE10A (0.63) | PDE10AGPBAR1CYSLTR1CYSLTR2CYP1A2 | |
| SCHEMBL9818433 | 0.84 | PDE10A (0.63) | PDE10AGPBAR1CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL10512475 | 0.82 | PDE10A (0.77) | PDE10AGPBAR1CYSLTR1CYSLTR2CYP1A2 | |
| SCHEMBL9637029 | 0.82 | GPBAR1 (0.69) | PDE10AGPBAR1CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL9719844 | 0.82 | PDE10A (0.60) | PDE10AGPBAR1CYSLTR1CYSLTR2CYP1A2 | |
| SCHEMBL8260654 | 0.82 | PDE10A (0.60) | PDE10AGPBAR1CYSLTR1CYSLTR2CYP1A2 | |
| SCHEMBL27816005 | 0.81 | CYSLTR1 (0.64) | PDE10AGPBAR1CYSLTR1CYSLTR2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |